Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi

This study has been completed.
Information provided by (Responsible Party):
Michael Sand, Ruhr University of Bochum Identifier:
First received: March 16, 2009
Last updated: October 15, 2012
Last verified: October 2012
MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study the researchers investigate the immunohistochemical distribution of Dicer in benign and dysplastic melanocytic naevi as well as in cutaneous malignant melanoma compared to intraindividual healthy control.

Malignant Melanoma

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Ruhr University of Bochum:

Biospecimen Retention:   Samples With DNA
Paraffin embedded melanocytic skin lesion

Enrollment: 30
Study Start Date: July 2008
Study Completion Date: March 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
benign melanocytic naevi
dysplastic melanocytic naevi
cutaneous malignant melanoma


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
dermatologic primary care clinic

Inclusion Criteria:

  • Patients with benign melanocytic naevi, dysplastic melanocytic naevi and cutaneous malignant melanoma.

Exclusion Criteria:

  • Patients under 18 years of age
  • Patients with other forms of cancer in previous medical history
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00862914

Department of Dermatology and Allergology, Ruhr-University Bochum
Bochum, NRW, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Principal Investigator: Prof. Dr. Peter Altmeyer Department of Dermatology and Allergology, Ruhr-University Bochum
Study Director: PD Dr. Falk G. Bechara Department of Dermatology and Allergology, Ruhr-University Bochum
  More Information

Responsible Party: Michael Sand, Dr., Ruhr University of Bochum Identifier: NCT00862914     History of Changes
Other Study ID Numbers: 006
Study First Received: March 16, 2009
Last Updated: October 15, 2012

Keywords provided by Ruhr University of Bochum:
Malignant Melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on May 23, 2017